Mednet Logo
SpecialtiesMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

Would you recommend adjuvant cisplatin/gemcitabine or nivolumab in a patient with muscle invasive bladder CA who proceeded to radical cystectomy first?

1
6 Answers

Mednet Member
Mednet Member
Medical Oncology · UC San Diego Health Moores Cancer Center

This is an excellent question and one we are seeing more and more in clinics these days now that the FDA has approved nivolumab for adjuvant therapy for patients with locally advanced urothelial carcinoma at high risk of recurrence after radical resection. This is based on data from CheckMate 274 wh...

If you are using talquetamab as bridging before BCMA CAR-T therapy, when do you assess for response and/or stop the talquetamab?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Chicago

I’m not fond of the talq approach based on personal experience, but the data looks quite good. Most patients only get about 2-3 full doses before cells are ready. I aim to get step-up dosing completed and then move to 0.8 mg/kg every 2 weeks. That is generally enough to obtain a durable and deep eno...

Does stopping anagrelide affect fibrosis in patients with ET who develop post-ET myelofibrosis?

1 Answers

Mednet Member
Mednet Member
Hematology · Johns Hopkins University

Anagrelide is a phosphodiesterase (PDE) III inhibitor, developed initially as a platelet antiaggregant, but was found to have platelet lowering activity at concentrations lower than its platelet antiaggregant activity. Thus, it was consequently marketed to reduce thrombocytosis in MPN patients. It i...

In what situations would you recommend adjuvant radiation therapy for patients with locally advanced and/or recurrent basal cell carcinoma that receive vismodegib followed by surgery?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Michigan Medical School

Adjuvant radiation therapy should be considered for locally advanced basal cell carcinomas when surgical margins are positive, or when there is perineural invasion, particularly in high-risk anatomical locations such as the face. This recommendation is endorsed by both the NCCN and the American Acad...

Does pre-chemotherapy extent of nodal involvement impact your decision to offer adjuvant radiation in cN1, ypN0 triple-negative breast cancer?

3
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Beth Israel Deaconess Medical Center

There are few data on this subject. The group at the Netherlands Cancer Institute in Amsterdam created what they called the "MARI" approach for such patients (Koolen et al., PMID 28524246). In brief, they performed an axillary ultrasound and marked the largest suspicious node with a radioactive seed...

Would you recommend an allogenic stem cell transplant in an older patient > 50 with Ph negative acute lymphoblastic leukemia who is MRD negative after induction?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Washington

In general, I would not routinely recommend allogeneic hematopoietic cell transplantation (HCT) for Ph- acute lymphoblastic leukemia (ALL) that is in MRD-negative remission this early in their treatment. This sort of response demonstrates significant chemosensitivity. Therefore, I would favor contin...

Would you recommend an allogenic stem cell transplant in an older patient > 50 with Ph negative acute lymphoblastic leukemia who is MRD negative after induction?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Washington

In general, I would not routinely recommend allogeneic hematopoietic cell transplantation (HCT) for Ph- acute lymphoblastic leukemia (ALL) that is in MRD-negative remission this early in their treatment. This sort of response demonstrates significant chemosensitivity. Therefore, I would favor contin...

How do you sequence chemotherapy with radiotherapy for advanced endometrial cancer?

6
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

Unfortunately, we don’t even know for sure if we need RT for stage III disease.GOG 258 showed early concurrent chemo RT is no better than chemotherapy alone (delaying chemo increased distant mets, which probably negated locoregional control benefit of RT). For this reason, chemotherapy has become st...

Would you consider substituting infusional 5FU for capecitabine in the FLOT regimen for localized gastric adenocarcinoma?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Memorial Sloan Kettering Cancer Center

No. I'm not aware of any high-quality data for such a regimen.

How do you manage PSA progression while a patient is on Xofigo or Pluvicto?

5
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Corewell Health

The tl;drPSA is very much an imperfect tool for these patients. The data show that PSA may initially increase over multiple cycles before decreasing, though this is a minority of patients. Most patients whose PSA increases early have resistant disease, and you should investigate further with imaging...